AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDT
Company Participants
Tryn Stimart – Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
Carl L. Hansen – CEO, President & Chairperson
Andrew Booth – Chief Financial Officer
Conference Call Participants
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Allison Bratzel – Piper Sandler & Co., Research Division
Brendan Smith – TD Cowen, Research Division
Debanjana Chatterjee – JonesTrading Institutional Services, LLC, Research Division
Presentation
Operator
Good afternoon, and welcome to AbCellera’s Q2 2026 Business Update Conference Call. My name is Jonathan, and I will facilitate the audio portion of today’s interactive broadcast. At this time, I would like to turn the call over to Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. You may proceed.
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
Thank you. Hello, everyone. Thank you for joining us for AbCellera’s Second Quarter 2026 Earnings Call. I’m Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. Dr. Carl Hansen, AbCellera’s President and CEO; and Andrew Booth, AbCellera’s Chief Financial Officer, are speaking on today’s call.
During this call, we may make statements about our strategic priorities and financial outlook based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described. Please review the Risk Factors section of our most recent Form 10-K and subsequent 10-Q filings with the SEC for a more detailed discussion of these risks. AbCellera assumes no obligation to update any forward-looking
